Maynard Um
-
-
-
-
-
-
-
Stifel Reiterates Xenon Pharmaceuticals (XENE) at Buy following Biohaven's failure
-
-
-
-
-
-
-
Wells Fargo Assumes Xenon Pharmaceuticals (XENE) at Overweight
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) PT Lowered to $55 at RBC Capital
-
-
-
-
-
-
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as COO
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

